Kairos Pharma (NYSEAMERICAN:KAPA) Earns “Buy” Rating from D. Boral Capital

Kairos Pharma (NYSEAMERICAN:KAPA)‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a report released on Wednesday,Benzinga reports. They currently have a $9.00 target price on the stock.

Kairos Pharma Price Performance

KAPA stock opened at $1.14 on Wednesday. Kairos Pharma has a twelve month low of $0.85 and a twelve month high of $4.00.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.